Detalles de la búsqueda
1.
Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis.
Rheumatology (Oxford)
; 61(2): 688-695, 2022 02 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33909900
2.
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort.
J Autoimmun
; 124: 102729, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34600347
3.
Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion.
Rheumatology (Oxford)
; 60(3): 1313-1320, 2021 03 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32940703
4.
Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis.
Ann Rheum Dis
; 79(8): 1077-1083, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32503858
5.
Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort.
Ann Rheum Dis
; 79(7): 943-950, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32321721
6.
Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission.
Rheumatology (Oxford)
; 59(7): 1591-1598, 2020 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31642908
7.
Pulmonary involvement in antisynthetase syndrome.
Curr Opin Rheumatol
; 31(6): 603-610, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31503025
8.
Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
Ann Rheum Dis
; 77(1): 104-110, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28970217
9.
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study.
J Autoimmun
; 86: 1-8, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28935492
10.
Physician's global assessment is often useful in SLE, but not always: the case of clinical remission.
Ann Rheum Dis
; 81(5): e77, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32434827
11.
The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients.
Ann Rheum Dis
; 76(3): 562-565, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27884821
12.
Correction to: Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis.
Rheumatology (Oxford)
; 61(8): 3506, 2022 Aug 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35217855
13.
Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis.
J Autoimmun
; 74: 94-105, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27373904
14.
Practice pattern for the use of intravenous iloprost for the treatment of peripheral vasculopathy in systemic sclerosis: A case-control study from the Italian national multicenter "SPRING" (Systemic Sclerosis Progression InvestiGation) Registry.
J Scleroderma Relat Disord
; 9(1): 38-49, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38333531
15.
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase.
J Transl Autoimmun
; 7: 100212, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37854035
16.
Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis.
Lupus Sci Med
; 9(1)2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35568438
17.
Belimumab: a step forward in the treatment of systemic lupus erythematosus.
Expert Opin Biol Ther
; 21(5): 563-573, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33630721
18.
Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up.
J Nephrol
; 34(2): 389-398, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32462476
19.
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
Arthritis Rheumatol
; 72(8): 1314-1324, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32275125
20.
Preclinical and early systemic lupus erythematosus.
Best Pract Res Clin Rheumatol
; 33(4): 101422, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31810542